Chemomab Therapeutics Ltd.
Data quality: 83%
CMMB
Nasdaq
Manufacturing
Chemicals
$1.69
▼
$0.03
(-1.46%)
Mkt Cap: 12.13 M
Price
$1.69
Mkt Cap
12.13 M
Day Range
$1.62 — $1.84
52-Week Range
$1.35 — $5.88
Volume
121,103
Open $1.71
50D / 200D Avg
$1.69
0.08% below
50D / 200D Avg
$2.76
39.04% below
Quick Summary
Key Takeaways
Negative free cash flow of -11.13 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-91.39%
Below sector avg (-51.02%)
ROIC-887.68%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio7.42
Interest CoverageN/A
Valuation
PE (TTM)
-1.35
Above sector avg (-1.98)
P/B Ratio1.25
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.4 | -2.0 |
| P/B | 1.3 | 5.1 |
| ROE % | -91.4 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -9.00 M |
| ROE | -91.39% | ROA | -70.07% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -11.13 M |
| ROIC | -887.68% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 7.42 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 9.18 M | Tangible Book Value | 9.70 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.35 | Forward P/E | N/A |
| P/B Ratio | 1.25 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -91.76% | ||
| Market Cap | 12.13 M | Enterprise Value | 6.68 M |
| Per Share | |||
| EPS (Diluted TTM) | 0.02 | Revenue / Share | N/A |
| FCF / Share | -1.55 | OCF / Share | -1.55 |
| EPS CAGR (1Y) | -53.85% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 123.77% |
| SBC-Adj. FCF | -12.86 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -9.00 M | -13.95 M | -24.22 M | -27.65 M | -12.48 M |
| EPS (Diluted) | 0.02 | 0.04 | 0.10 | 0.12 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -112.00 M | -103.00 M | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 5.83 M | 11.33 M | 18.38 M | 16.98 M | 6.33 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | -534,000.0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 13.81 M | 16.96 M | 22.15 M | 43.06 M | 64.35 M |
| Total Liabilities | 1.48 M | 3.43 M | 5.15 M | 6.84 M | 2.89 M |
| Shareholders' Equity | 12.33 M | 13.54 M | 17.00 M | 36.22 M | 61.47 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 7.56 M | 6.07 M | 9.29 M | 13.52 M | 15.19 M |
| Current Assets | 13.43 M | 16.04 M | 20.90 M | 41.74 M | 62.69 M |
| Current Liabilities | 1.48 M | 3.22 M | 4.84 M | 6.75 M | 2.65 M |
{"event":"ticker_viewed","properties":{"ticker":"CMMB","listing_kind":"stock","pathname":"/stocks/cmmb","exchange":"Nasdaq","country":"US"}}